Intratumour heterogeneity is a critical driver of cancer progression and treatment failure. TRACERx Renal is a prospective study that aims to define the evolutionary trajectories of renal cancer in space and time through multiregion and longitudinal tumour sampling.
This is a preview of subscription content, log in via an institution to check access.
References
Turajlic, S., Larkin, J. & Swanton, C. SnapShot: renal cell carcinoma. Cell 163, 1556–1556.e1 (2015).
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03004755 (2016).
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Hsieh, J. J. et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur. Urol. 71, 405–414 (2017).
Turajlic, S. & Swanton, C. Implications of cancer evolution for drug development. Nat. Rev. Drug Discov. http://dx.doi.org/10.1038/nrd.2017.78 (2017).
Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169–175 (2016).
Acknowledgements
S.T. is funded by Cancer Research UK (CRUK; grant reference number C50947/A18176) and the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109). C. S. is funded by CRUK (TRACERx), the Rosetrees Trust, NovoNordisk Foundation (ID 16584), EU FP7 (projects PREDICT and RESPONSIFY, ID: 259303), the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council (THESEUS) and NIHR University College London Hospitals BRC.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
S.T. declares no competing interests. C.S. is a consultant for Novartis and Roche, has received speaker's fees from Boehringer Ingelheim, Celgene, Eli Lilly, Epic Biosciences, GlaxoSmithKline, Grail Scientific, Novartis, Pfizer, Roche, and Servier, he is on the advisory board and has stock options of APOGEN Biotechnologies, EPIC Biosciences, and Grail Scientific, and is a founder of and has stock options from Achilles Therapeutics.
Related links
FURTHER INFORMATION
Supplementary information
Supplementary information S1 (Figure)
Overview of sampling, tissue processing, and analysis in TRACERx Renal (PDF 472 kb)
Rights and permissions
About this article
Cite this article
TRACERx Renal consortium. TRACERx Renal: tracking renal cancer evolution through therapy. Nat Rev Urol 14, 575–576 (2017). https://doi.org/10.1038/nrurol.2017.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.112
- Springer Nature Limited
This article is cited by
-
Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study
Cancer Imaging (2023)
-
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Nature Communications (2021)
-
2019 ASCO Genitourinary Cancers Symposium
Nature Reviews Urology (2019)
-
Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma
Current Urology Reports (2018)